CHICAGO — More individuals with advanced cancers in the U.S. live within 30 miles of a clinical trial site than a decade ago, but those in rural areas, those with pancreatic disease and American Indians/Alaskan Natives still have access issues.
According to data presented at ASCO Annual Meeting and simultaneously published in JAMA Oncology, 65.7% of patients with metastatic pancreatic cancer reside within 30 miles of a relevant clinical trial site.
The rates have gone up considerably compared with those published in 2015 for patients with breast cancer (81.8% vs. 45.6%), prostate cancer